文献速递冠心病

TAVR 改善癌症合并重度主动脉瓣狭窄患者的抗癌治疗连续性与生存

Transcatheter Aortic Valve Replacement Facilitates Anti‐Cancer Therapy Continuity and Improves Survival in Cancer Patients
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-09-30

本研究回顾性纳入 183 例因重度主动脉瓣狭窄接受 TAVR 或 SAVR 的癌症患者,采用逆概率加权比较抗癌治疗连续性与生存结局。结果显示,TAVR 组 90 天治疗恢复率更高、恢复时间更短,且心脏相关中断更少。治疗延迟与癌症死亡率呈剂量反应关系,提示需及时新辅助治疗者可能优先选择 TAVR。

要点

  • TAVR 组 90 天抗癌治疗恢复率为 83.7%,SAVR 组为 56.3%。
  • 每延迟 30 天恢复治疗,癌症死亡风险增加 15%。
  • TAVR 减少非致命性心脏相关治疗中断(6.9% vs 17.1%)。

核心结论

  • TAVR 相比 SAVR 与更高的抗癌治疗连续性及更少的心脏相关中断相关。
  • 抗癌治疗延迟与癌症死亡率之间存在剂量依赖性关联。
  • 对于需要及时新辅助治疗的患者,TAVR 可能是优选策略,但需前瞻性验证。

研究设计与样本

  • 回顾性研究纳入 2018 年 6 月至 2024 年 12 月因重度主动脉瓣狭窄接受 TAVR 或 SAVR 的癌症患者 183 例,其中 TAVR 组 101 例,SAVR 组 82 例。
  • 采用逆概率加权平衡组间差异,并进行敏感性、界标及剂量反应分析。
  • 主要终点为 90 天抗癌治疗恢复,采用 Fine-Gray 竞争风险回归分析。

主要发现

  • TAVR 组 90 天治疗恢复率为 83.7%,SAVR 组为 56.3%(OR 3.51,p < 0.001)。
  • TAVR 组恢复治疗中位时间为 28 天,SAVR 组为 75 天(sHR 2.45,p < 0.001)。
  • 每延迟 30 天恢复治疗,癌症死亡率增加 15%(HR 1.15,p = 0.01)。
  • TAVR 组非致命性心脏相关中断发生率为 6.9%,SAVR 组为 17.1%(OR 0.28,p = 0.01)。
  • 治疗中断独立预测全因死亡(HR 1.48,p = 0.001),排除进展相关中断后仍显著(HR 1.32,p = 0.02)。

关键数值与推荐

  • 90 天抗癌治疗恢复率:TAVR 83.7% vs SAVR 56.3%,OR 3.51,p < 0.001。
  • 恢复治疗时间:TAVR 28 天 vs SAVR 75 天,sHR 2.45,p < 0.001。
  • 非致命性心脏相关中断:TAVR 6.9% vs SAVR 17.1%,OR 0.28,p = 0.01。
  • 每 30 天治疗延迟与癌症死亡率:HR 1.15,p = 0.01。
  • 新辅助治疗亚组获益最显著,交互作用 p = 0.04。

临床怎么用

  • 癌症合并重度主动脉瓣狭窄且需及时抗癌治疗者,可优先考虑 TAVR 以缩短治疗中断时间。
  • 需新辅助治疗的患者从 TAVR 中获益可能更大,应在瓣膜策略选择时纳入考量。

局限性

  • 本研究为单中心回顾性设计,存在残余混杂和选择偏倚风险。
  • 由于采用逆概率加权和观察性数据,结果需要在随机对照试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background The impact of transcatheter (TAVR) versus surgical aortic valve replacement (SAVR) on multi-dimensional anti‑cancer therapy continuity and survival in cancer patients with severe aortic stenosis (AS) remains unknown. Aims To assess whether TAVR, compared with SAVR, is associated with superior anti-cancer therapy continuity and survival in cancer patients with severe AS. Methods We conducted a retrospective study of cancer patients undergoing TAVR or SAVR for severe AS from June 2018 to December 2024. Inverse probability of treatment weighting (IPTW) was used. Endpoints included 90‑day therapy resumption (primary; Fine−Gray competing risk regression), 1‑year completion, cardiac‑related interruptions, and mortality. Sensitivity, landmark, and dose−response analyses were performed. Results Among 183 patients (TAVR: 101, SAVR: 82), IPTW achieved excellent balance. TAVR was associated with higher 90‑day resumption (83.7% vs. 56.3%; OR 3.51, p < 0.001) and shorter time to resumption (28 vs. 75 days; sHR 2.45, p < 0.001). A dose−response relationship was observed: each 30‑day delay increased cancer mortality by 15% (HR 1.15, p = 0.01). TAVR reduced non‑fatal cardiac‑related interruptions (6.9% vs. 17.1%; OR 0.28, p = 0.01). Therapy interruption independently predicted all‑cause mortality (HR 1.48, p = 0.001), even after excluding progression‑related interruptions (sensitivity HR 1.32, p = 0.02). Landmark analysis at 3 months showed better subsequent survival with early resumption (HR 0.61, p = 0.01). Benefits were most pronounced in neoadjuvant patients (interaction p = 0.04). Competing risk analysis showed lower 3‑year cardiovascular mortality with TAVR (4% vs. 12%; p = 0.04). Conclusions TAVR was associated with superior therapy continuity and fewer cardiac interruptions. A dose‑dependent association between treatment delay and cancer mortality was observed. These findings suggest that TAVR may be preferred in patients requiring timely neoadjuvant therapy, but prospective validation is needed.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Transcatheter Aortic Valve Replacement Facilitates Anti‐Cancer Therapy Continuity and Improves Survival in Cancer Patients

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。